Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is indicated for the management of high blood pressure, helps protect kidney function in patients with diabetes, and can be part of therapy for heart failure in adult patients.

GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics across multiple regions worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics.

Irbesartan acts on the renin‑angiotensin system to lower blood pressure and protect target organs.

- Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk control. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: contributes to reduced morbidity by decreasing afterload and improving symptoms.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: transient light‑headedness that may occur upon standing quickly, usually resolves with rest. - Headache: mild to moderate pressure sensation, often relieved by over‑the‑counter analgesics. - Fatigue: general tiredness without specific cause, may affect daily activities but often improves over time. - Diarrhea: loose stools occurring intermittently, usually self‑limiting and not requiring medical intervention.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium levels that can lead to cardiac rhythm disturbances and require urgent treatment. - Acute kidney injury: sudden decline in renal function manifested by increased creatinine, necessitating close monitoring and possible dose adjustment. - Angioedema: swelling of the face, lips, tongue, or airway that can become life‑threatening and requires immediate medical attention.

When prescribing Irbesartan, several precautions should be observed to ensure safe use. - Renal function monitoring: assess serum creatinine and eGFR before initiation and periodically. - Serum potassium: check potassium levels regularly, especially in patients with renal impairment or on potassium‑sparing agents. - Concomitant NSAIDs: avoid or use with caution as they may reduce antihypertensive effect and worsen renal function. - Pregnancy: contraindicated in pregnancy due to risk of fetal toxicity; discontinue if pregnancy occurs. - Volume depletion: correct dehydration before starting therapy to prevent symptomatic hypotension. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and light.

Irbesartan may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients can increase risk of renal impairment, hyperkalemia, and hypotension. - Lithium: concurrent use may raise lithium concentrations, leading to toxicity. - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): may cause excessive hypotension, renal dysfunction, and hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can diminish antihypertensive effect and impair renal function. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia. - Diuretics: may potentiate hypotensive effect, requiring dose adjustment.